In this interview, News Medical speaks with LexisNexis® Risk Solutions’ Healthcare Business about optimizing clinical trial screening and digital health programs through better understanding of consumer consent data.
How is data currently used with consumer consent in clinical trials and digital health programs?
Data with consumer consent refers to personal information that individuals have expressly agreed to share with an organization for specific purposes. It is used in clinical trials and digital health programs primarily to streamline the patient screening process and improve recruitment efficiency. This data includes Electronic Health Records (EHR), lab results, and real-time health data from mobile devices. Using this data in clinical trial screening and recruitment processes helps research teams quickly assess patients’ eligibility to participate in a clinical trial. When implemented as part of digital health applications and workflows, consumer-consented health data helps create a more complete picture of a consumer in exchange for more personalized recommendations and programs that may better motivate the consumer to take action on improving his health.
Image Credit: PeopleImages.com – Yuri A/Shutterstock.com
What are the main benefits of using consumer consent data to screen patients in clinical trials and optimize a digital health program?
The primary benefits of using consumer consent data in clinical trials are increased efficiency, improved patient safety, and improved enrollment. Access to the most up-to-date, comprehensive medical records improves accuracy in patient eligibility assessments, significantly reducing screening and enrollment times. When a clinical trial team can minimize delays in these essential and often previously manual, time-consuming and demanding processes, they can also achieve significant cost reductions in the conduct of their trial, where every day has a significant financial impact.
What are the industry’s main challenges in integrating consumer consent data into patient screening processes in clinical trials?
The main challenge of using data with consumer consent in clinical trials is the fragmentation of data, as patient records are often scattered across different healthcare providers, which complicates the compilation of a complete medical history. Privacy regulations like HIPAA and GDPR add complexity to this challenge. Technological barriers arise from differences in how health records are stored and accessed, slowing data retrieval. Additionally, ensuring patient understanding and consent requires an ongoing commitment to clear communication and often requires the development of robust educational resources.
How do you address data privacy and security concerns when dealing with consumer consent data in clinical trials?
Addressing data privacy and security involves implementing advanced technologies and adhering to strict regulations such as HIPAA and GDPR. Key measures include encrypting data both in transit and at rest, limiting access to authorized personnel through strict access controls, maintaining detailed audit trails for accountability, and ensuring transparent consent processes with clear information to patients on how to use and protect of their data.
Are there regulatory challenges associated with using consumer consent data in clinical trials, and how can these challenges be mitigated?
Most of the regulatory challenges revolve around compliance with various privacy laws and directives. Mitigation strategies include standardizing data formats using industry standard coding systems such as ICD-10 and SNOMED for consistency, implementing compliance frameworks to ensure all data management processes comply with relevant regulations, and providing ongoing training with regular training of staff on regulatory requirements and best practices.
What strategies can encourage patients to consent to sharing their data for clinical trials and digital health programs?
Strategies to encourage patient consent include clearly explaining the benefits and uses of their data to promote transparency. The use of user-friendly consent forms and interfaces can simplify the process and reduce patient burden. Additionally, providing educational resources and involving patients in trial design helps address their concerns and preferences, fostering a more patient-centered approach.
How do you ensure the quality and reliability of consumer consent data used to screen patients in clinical trials?
Ensuring the quality and reliability of consumer consent data involves several key strategies. Data verification involves cross-checking data from multiple sources to ensure accuracy. Data standardization involves normalizing data using industry standard coding schemes. Ongoing monitoring is important to regularly check data for consistency and completeness. Finally, the use of advanced technologies and powerful data integration tools help minimize errors and maintain data integrity. These measures collectively ensure that the data used in clinical trials are reliable and of high quality.
Image credit: Raker/Shutterstock.com
What ethical aspects should be considered when leveraging consumer consent data in clinical trials and digital health initiatives?
Ethical considerations when using data with consumer consent in clinical trials involve several key principles. Informed consent is paramount because you need to ensure that patients fully understand how their data will be used and the implications of their participation. Privacy and confidentiality must be strictly maintained through strict data protection protocols to protect sensitive information.
Equity is another critical factor, ensuring that the benefits of research are fairly distributed and that diverse populations are included in trials to improve the generalizability of findings. And finally, transparency is essential. Maintaining transparency about data use helps build and maintain trust with participants. Together, these form a framework to ensure that clinical trials are conducted respectfully, inclusively and responsibly.
What future trends do you foresee in using consumer consent data to optimize clinical trials and digital health programs? How can the industry prepare for these changes?
Future trends in clinical trials and digital health programs include the increasing use of artificial intelligence and machine learning to quickly analyze large data sets and more efficiently identify eligible patients. There will also be greater integration of real-time health data from wearables and other devices, enabling continuous monitoring and timely interventions. Personalized medicine will likely become more prevalent, with integrated data analytics enabling more tailored approaches to patient care. Improved data integration technologies will also facilitate the seamless flow of data from various sources, improving overall performance.
The industry can prepare for these changes by investing in advanced technologies, implementing best practices focused on patient engagement, fostering stakeholder collaboration, and continually updating compliance and ethical standards to adapt to an ever-changing landscape.
About LexisNexis® risk solutions
LexisNexis® Risk Solutions leverages the power of data, sophisticated analytics platforms and technology solutions to deliver insights that help businesses across multiple industries and government
Entities reduce risk and improve decisions for the benefit of people around the world. Headquartered in metro Atlanta, Georgia, we have offices around the world and are part of RELX (LSE: REL/NYSE: RELX), a global provider of analytics and information-based decision-making tools for professional and enterprise customers. For more information, visit LexisNexis Risk Solutions and RELX.
